Human platelet lysate enhances the proliferation of Wharton's jelly-derived mesenchymal stem cells

Antoninus, Andreas Ardhika; Widowati, Wahyu; Wijaya, Laura; Agustina, Dwi Martha; Puradisastra, Sugiarto; Sumitro, Sutiman Bambang; Widodo, M. Aris; Bachtiar, Indra

doi:10.1016/j.bgm.2015.06.001

Cited by 24 publications

(37 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…VBD concentrations added to culture medium ranged from 0.5 to 30% (54)(55)(56). Overall, VBD allowed for either, maintenance of MCS's fibroblast-like morphology (17,43,57), high proliferation (58-60), high colony-formation ability (52,61,62) and maintenance of multipotency (63)(64)(65)(66)(67). A linear dose-dependent response regarding medium concentration was not observed for evaluated VBD (54,56,68).…”

Section: Resultsmentioning

confidence: 96%

“…To reduce the barriers arising from the use of xenogeneic materials and to allow the clinical acceptance of SC-BT, venous blood derivatives (VBD) has been widely considered to be applied as FBS substitutes (17)(18)(19)(20). Venous blood is a source that can be easily obtained in a large volume from blood banks or from the own patient, decreasing the barriers for the use of SC-BT (2,8,9).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Venous Blood Derivatives as FBS-Substitutes for Mesenchymal Stem Cells: A Systematic Scoping Review

et al. 2017

View full text Add to dashboard Cite

Although the biological properties of mesenchymal stem cells (MSC) are well-characterized in vitro, MSC clinical application is still far away to be achieved, mainly due to the need of xenogeneic substances for cell expansion, such as fetal bovine serum (FBS). FBS presents risks regarding pathogens transmissions and internalization of animal's proteins, which can unleash antigenic responses in patients after MSC implantation. A wide range of venous blood derivatives (VBD) has been reported as FBS substitutes showing promising results. Thus, the aim of this study was to conduct a systematic scoping review to analyze whether VBD are effective FBS substitutes for MSC ex vivo expansion. The search was performed in SciVerse Scopus TM , PubMed, Web of Science TM , BIREME, Cochrane library up to January 2016. The keywords were selected using MeSH and entry terms. Two independent reviewers scrutinized the records obtained considering specific inclusion criteria. The included studies were evaluated in accordance with a modified Arksey and O' Malley's framework. From 184 found studies, 90 were included. Bone marrow mesenchymal stem cells (BMMSC) were presented in most of these studies. Overall, VBD allowed for either, maintenance of MCS's fibroblast-like morphology, high proliferation, high colony-formation ability and maintenance of multipotency. Besides. MSC expanded in VBD supplements presented higher mitogen activity than FBS. VBD seems to be excellent xeno-free serum for ex vivo expansion of mesenchymal stem cells. However, an accentuated heterogeneity was observed between the carried out protocols for VBD isolation did not allowing for direct comparisons between the included studies.

show abstract

Section: Resultsmentioning

confidence: 96%

Section: Introductionmentioning

confidence: 99%

Venous Blood Derivatives as FBS-Substitutes for Mesenchymal Stem Cells: A Systematic Scoping Review

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Using PL as a xenogeneic-free and effective substitute for FBS in MSCs culture was also addressed in other studies, which showed that culturing MSCs in PL-supplemented media maintained both the immunophenotype profile and the differentiation potency of MSCs [13, 19–21]. However, previous studies did not focus on the possibility to use PL as a substitute for recombinant growth factors in chondrogenic differentiation of MSCs [13, 19–21].…”

Section: Discussionmentioning

confidence: 99%

“…However, previous studies did not focus on the possibility to use PL as a substitute for recombinant growth factors in chondrogenic differentiation of MSCs [13, 19–21]. …”

Section: Discussionmentioning

confidence: 99%

Platelet lysate induces chondrogenic differentiation of umbilical cord-derived mesenchymal stem cells

et al. 2018

View full text Add to dashboard Cite

PurposeArticular cartilage has a poor capacity for self-repair, and thus still presents a major challenge in orthopedics. Mesenchymal stem cells (MSCs) are multipotent stem cells with the potential to differentiate into chondrocytes in the presence of transforming growth factor beta (TGF-β). Platelet lysate (PL) contains a relatively large number of growth factors, including TGF-β, and has been shown to ameliorate cartilage repair. Here, we investigated the ability of PL to direct chondrogenic differentiation of MSCs along with other standard differentiation components in a pellet culture system.MethodsWe isolated and expanded MSCs from human umbilical cords using a PL-supplemented medium and characterized the cells based on immunophenotype and potential for differentiation to adipocytes and osteocytes. We further cultured MSCs as pellets in a chondrogenic-differentiation medium supplemented with PL. After 21 days, the pellets were processed for histological analysis and stained with alician blue and acridine orange. The expression of SOX9 was investigated using RT-PCR.ResultsMSCs maintained their stemness characteristics in the PL-supplemented medium. However, the distribution of cells in the pellets cultured in the PL-supplemented chondrogenic differentiation medium had a greater similarity to cartilage tissue-derived chondrocytes than to the negative control. The intense alician blue staining indicated an increased production of mucopolysaccharides in the differentiated pellets, which also showed elevated expression of SOX9.ConclusionsOur data suggest that MSCs could be differentiated to chondrocytes in the presence of PL and absence of exogenous TGF-β. Further research needs to be conducted to understand the exact role and potential of PL in chondrogenic differentiation and chondrocyte regeneration.

show abstract

“…FFP is blood product made from the liquid portion of whole blood, it used as part of plasma exchange, a complex mixture of water, proteins, carbohydrates, fats, and vitamins, and has similar characteristic as Platelet Rich Plasma (PRP) [18]. The WJ-MSCs cultured in medium supplemented with human platelet from donor with blood type O and AB (huPL-ABO) had lower PDT compared to FBS medium in passage 1 to 8 [19]. Growth factors released by platelets in huPL-ABO are effective to stimulate proliferation of WJ-MSCs in vitro [19], this result was in line with previous study that hATMSCs cultured in FFP resulted higher proliferation or lower PDT compared to non FFP medium [20].…”

Section: Discussionmentioning

confidence: 99%

Growth factors profile in conditioned medium human adipose tissue-derived mesenchymal stem cells (CM-hATMSCs)

Noverina

Widowati

Ayuningtyas

et al. 2019

Clinical Nutrition Experimental

Self Cite

View full text Add to dashboard Cite

Human platelet lysate enhances the proliferation of Wharton's jelly-derived mesenchymal stem cells

Cited by 24 publications

References 33 publications

Venous Blood Derivatives as FBS-Substitutes for Mesenchymal Stem Cells: A Systematic Scoping Review

Venous Blood Derivatives as FBS-Substitutes for Mesenchymal Stem Cells: A Systematic Scoping Review

Platelet lysate induces chondrogenic differentiation of umbilical cord-derived mesenchymal stem cells

Growth factors profile in conditioned medium human adipose tissue-derived mesenchymal stem cells (CM-hATMSCs)

Contact Info

Product

Resources

About